These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 24394929)

  • 1. Why I will continue to screen prostate-specific antigen for myself and other appropriate men.
    Keller DL
    JAMA Intern Med; 2014 Jan; 174(1):164. PubMed ID: 24394929
    [No Abstract]   [Full Text] [Related]  

  • 2. Why I will continue to screen prostate-specific antigen for myself and other appropriate men--reply.
    Katz MH
    JAMA Intern Med; 2014 Jan; 174(1):164. PubMed ID: 24394931
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate-specific antigen testing in france.
    Braillon A
    JAMA Intern Med; 2013 Nov; 173(21):2014. PubMed ID: 24276059
    [No Abstract]   [Full Text] [Related]  

  • 4. Can we stop ordering prostate-specific antigen screening tests?
    Katz MH
    JAMA Intern Med; 2013 May; 173(10):847-8. PubMed ID: 23588841
    [No Abstract]   [Full Text] [Related]  

  • 5. Numbers needed to decide.
    Woloshin S; Schwartz LM
    J Natl Cancer Inst; 2009 Sep; 101(17):1163-5. PubMed ID: 19671771
    [No Abstract]   [Full Text] [Related]  

  • 6. Number needed to screen--how can we project outside context?
    Auvinen A
    J Clin Epidemiol; 2011 Dec; 64(12):1275-6. PubMed ID: 22032752
    [No Abstract]   [Full Text] [Related]  

  • 7. The Problem Is Not What to Do with Indolent and Harmless Prostate Cancer-The Problem Is How to Avoid Finding These Cancers.
    Gandaglia G; Briganti A; Fossati N; Salonia A; Mottrie A; Catto J; Montorsi F
    Eur Urol; 2016 Oct; 70(4):547-548. PubMed ID: 26916048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
    Taneja SS
    J Urol; 2015 Jan; 193(1):127. PubMed ID: 25523657
    [No Abstract]   [Full Text] [Related]  

  • 9. Patients Present with More Advanced Prostate Cancer since the USPSTF Screening Recommendations.
    Barry MJ; Nelson JB
    J Urol; 2015 Dec; 194(6):1534-6. PubMed ID: 26384450
    [No Abstract]   [Full Text] [Related]  

  • 10. Reconsidering Prostate Cancer Screening.
    Schmidt C
    J Natl Cancer Inst; 2017 Jan; 109(1):1-2. PubMed ID: 28104781
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Prostate-specific antigen-based prostate cancer screening: Past and future.
    Birkeland S
    Int J Urol; 2016 Apr; 23(4):348. PubMed ID: 26839978
    [No Abstract]   [Full Text] [Related]  

  • 12. Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy.
    Mishra VC; Motiwala HG
    BJU Int; 2004 May; 93(7):1116-7. PubMed ID: 15142181
    [No Abstract]   [Full Text] [Related]  

  • 13. Editorial Comment to Prostate-specific antigen-based prostate cancer screening: Past and future.
    Sakamoto S
    Int J Urol; 2015 Jun; 22(6):532-3. PubMed ID: 25854711
    [No Abstract]   [Full Text] [Related]  

  • 14. The rate of overdiagnosis inextricably linked to prostate-specific antigen-based screening for prostate cancer can be quantified in several ways, but what is the practicable message?
    Roobol MJ; Schröder FH
    Eur Urol; 2014 Jun; 65(6):1056-7. PubMed ID: 24486022
    [No Abstract]   [Full Text] [Related]  

  • 15. Individualized prostate-specific antigen threshold values to avoid overdiagnosis of prostate cancer and reduce unnecessary biopsy in elderly men.
    Kanao K; Komori O; Nakashima J; Ohigashi T; Kikuchi E; Miyajima A; Nakagawa K; Eguchi S; Oya M
    Jpn J Clin Oncol; 2014 Sep; 44(9):852-9. PubMed ID: 25030213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Legal pitfalls in the diagnosis of prostate cancer.
    Dunn IB; Kirk D
    BJU Int; 2000 Aug; 86(3):304-7. PubMed ID: 10930937
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?
    Duffy MJ
    Ann Clin Biochem; 2011 Jul; 48(Pt 4):310-6. PubMed ID: 21525152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [You have to take the prostate cancer seriously].
    Stief CG
    MMW Fortschr Med; 2012 Jan; 154(1):42. PubMed ID: 22642002
    [No Abstract]   [Full Text] [Related]  

  • 19. [Prostate cancer screening: no proof of the benefit].
    Laplanche A; Hill C
    Presse Med; 2009 Oct; 38(10):1393-5. PubMed ID: 19647979
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up.
    Braillon A; Dubois G
    J Natl Cancer Inst; 2012 May; 104(10):793; author reply 793-4. PubMed ID: 22491229
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.